Clinical Trial

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

Study acronym: BLADE-VG2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2022-09-12; most recent amendment 2025-06-23.
Status change: Recruiting → Active, Not Recruiting 2025-06-23
Status change: Not Yet Recruiting → Recruiting 2023-02-01
Trial Details
NCT Number NCT05539963
Lead Sponsor Biocomposites Ltd
Collaborators: MCRA
Conditions Diabetic Foot Osteomyelitis
Enrollment 61 participants
Start Date 2023-01-23
Primary Completion 2025-06-20 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-24